Redbord Kelley Pagliai, Hanke C William
Laser and Skin Surgery Center of Indiana, St. Vincent Hospital, Indianapolis, IN 46032, USA.
J Drugs Dermatol. 2007 Dec;6(12):1197-202.
Topical photodynamic therapy (PDT) involves the use of a photosensitizing topical medication that is activated by a light source in the presence of oxygen leading to cellular destruction and subsequent photorejuvenation. In 1999, the US FDA approved PDT for the treatment of nonhyperkeratotic actinic keratoses (AKs) on the face and scalp.
The study population comprised 85 patients treated with short-contact, topical aminolevulinic acid (ALA)-PDT for a total of 247 treatments. Ninety percent of patients with a variety of dermatologic disorders had significant improvement or total clearance. Ninety-eight percent of patients had no complications. Only 2 patients in our series had a significant complication.
Short-contact, topical ALA-PDT is a safe and effective treatment for a variety of dermatologic disorders including photoaging and AKs.
局部光动力疗法（PDT）涉及使用一种光敏性局部用药，该药物在氧气存在下由光源激活，导致细胞破坏并随后实现皮肤年轻化。1999年，美国食品药品监督管理局（FDA）批准PDT用于治疗面部和头皮的非角化过度性光化性角化病（AKs）。
研究人群包括85例接受短接触局部氨基酮戊酸（ALA）-PDT治疗的患者，共进行了247次治疗。90%患有各种皮肤病的患者有显著改善或完全清除。98%的患者无并发症。我们系列中只有2例患者出现严重并发症。
短接触局部ALA-PDT是治疗包括光老化和AKs在内的各种皮肤病的一种安全有效的方法。
